Table 1 Clinical characteristics, therapy and outcome of ALL cases reported with e1a3 fusion protein compared with those presented in this manuscript
From: Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
# | Age | Leukocite count at Dx | BM infiltration | TKI | SCT | Status | Response | References |
|---|---|---|---|---|---|---|---|---|
1 | 65 years | 223 × 103 | 25 % | Imatinib | – | Dead | Refractory | Current |
2 | 43 years | 133 × 103 | 90 % | Imatinib | AlloSCT (ongoing) | Alive | CR | Current |
3 | 76 years | 7000 | 85 % | Dasatinib | – | Alive | CR | Sonu [12] |
4 | Unk | 5.530 × 109/L | 90 % | Imatinib | Allo SCT | Alive | CR | Shin 13] |
5 | Unk | 24.36 × 109/L | 80 % | Imatinib | – | Dead | Not achieved | Shin [13] |
6 | 80 years | 94 % at blast crisis | Imatinib | – | Dead | CML transformed to B-ALL | Martinez-Serra [1] | |
7 | 62 years | NA | NA | Imatinib | – | Dead | relapse | Langabeer [14] |
8 | 25 years | NA | NA | – | 2d AlloSCT | Dead | Relapse/VOD | Fujisawa [15] |
9 | 62 years | 10 | NA | – | Autologous | Dead | relapse | Burmeister [16] |
10 | 64 years | 1.8 | NA | – | – | Dead | relapse | Burmeister [16] |
11 | 31 years | 31 | NA | Imatinib | Allo SCT | Alive | CCR | Burmeister [16] |
12 | 61years | 14 | NA | Imatinib | – | Alive | CCR | Burmeister [16] |
13 | 48 years | 62 | NA | – | – | Dead | Relapse | Burmeister [16] |
14 | 37 years | 70 | NA | Imatinib | AlloSCT | Alive | CCR | Burmeister [16] |
15 | 45 years | 5 | NA | Imatinib | AlloSCT | Alive | CCR | Burmeister [16] |
16 | 29 years | 40 | NA | Imatinib | AlloSCT | Alive | CCR | Burmeister [16] |
17 | NA | NA | NA | NA | NA | NA | NA | Wilson [17] |
18 | 1 year | NA | NA | NA | NA | Dead | NA | Iwata [18] |
19 | 39 years | NA | NA | NA | NA | Dead | NA | Soakerman [19] |
20 | NA | NA | NA | NA | NA | NA | NA | Chen [20] |